AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Venclexta (venetoclax) is a prescription drug that’s used to treat certain blood cancers. Venclexta comes as an oral tablet. Venclexta is used in adults to treat the following cancers in certain ...

Venclexta (venetoclax) can cause side effects that range from mild to serious. More common side effects include nausea, diarrhea, and anemia. If side effects from Venclexta become difficult to ...

Venclexta (venetoclax) is a brand-name oral tablet prescribed for certain types of cancer in adults. As with other drugs, Venclexta can cause side effects, such as nausea, fatigue, or dizziness.

Venclexta (venetoclax) is a brand-name oral tablet that’s prescribed for newly diagnosed acute myeloid leukemia (AML) in certain adults. This article covers topics such as side effects ...

Venclexta (ven-KLEKS-tuh) was approved in 2019 for the treatment of CLL and SLL. The medicine works to stop the growth and spread of cancer cells. Your health care provider may prescribe Venclexta ...

The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS). The VERONA study ...